Immunogenicity and safety of a bivalent, adjuvant system 04–adjuvanted human papillomavirus vaccine in healthy female volunteers aged 15–25: a randomized, double-blind, phase III, noninferiority clinical trial Afshani, Seyyedeh Maryam; Mirhassani, Reihaneh; Hosseini, Hamed; More Afshani, Seyyedeh Maryam; Mirhassani, Reihaneh; Hosseini, Hamed; Hosseini, Reihaneh; Tehranian, Afsaneh; Malekzadeh, Reza; Ostovar, Afshin; Abdolghaffari, Amir Hossein; Ghobadi, Mohammad Amin; Hedayatjoo, Behnaz; Hazegh Fetratjoo, Delara; Rezagholi, Zahra; Anari, AmirHossein; Moini, Ashraf Less European Journal of Cancer Prevention. 31(6):558-567, November 2022. Abstract Abstract Favorite PDF Permissions Buy
